HIV-1 infection, multidrug-resistant
Infectious disease · 2022–2022
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenacapavir Treatment of patients with highly multidrug-resistant HIV-1 infection who have no more than two fully active antiretrovirals remaining from the four main… | Nov 2022 | Not recommended | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.